Biomarkers of ionizing radiation

The present invention provides novel radiation associated markers. The radiation associated markers may be one or more of albumin, LTGF-β, or any protein or peptide listed in any one of Tables 1, 2, 3, 4, 5, and 6 provided herein. The present invention also provides methods of assessing exposure to ionizing radiation by determining the presence of one or more radiation associated markers. The methods may optionally include quantifying one or more of the radiation associated markers. The methods may further include comparing the amount of one or more radiation associated markers in the sample determined to be present in the sample with either (i) the amount determined for temporally matched, normal samples or (ii) the amount determined for samples obtained from individuals or subjects that have not been exposed to an elevated level of ionizing radiation. The present invention further provides a method of predicting outcome in a subject after exposure to elevated levels of ionizing radiation. Further, the present invention provides a method of determining the amount of radiation therapy that has been delivered to a particular tissue. Also, the present invention provides kits for assessing the likelihood of significant damage, death, illness or medical complications post exposure to elevated levels of ionizing radiation by determining the presence or absence or by quantifying the amount of one or more radiation associated markers.